DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

03 Sep 2024 07:00:27 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

14 Aug 2024 13:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

01 Aug 2024 05:45:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

03 Jun 2024 07:00:40 By Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

07 May 2024 15:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

01 May 2024 07:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

27 Feb 2024 07:05:54 By Nasdaq GlobeNewswire

Denali Therapeutics Announces $500 million Private Placement Equity Financing

27 Feb 2024 07:00:37 By Nasdaq GlobeNewswire

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

07 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

01 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

08 Jan 2024 07:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

07 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

30 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

08 Aug 2023 15:01:27 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

20 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

08 May 2023 15:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

10 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

27 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

22 Feb 2023 15:33:24 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

15 Feb 2023 15:01:00 By Nasdaq GlobeNewswire